



S/10/082,925

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: John E. More et al.

Examiner: Abdel Mohamed

Serial No.: 10/082,925

Group Art Unit: 1653

Filed: February 26, 2002

Docket: 697.004US2

Title: PURIFICATION METHOD

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop RCE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. § 1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Information Disclosure Statement considered.

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,  
JOHN E. MORE ET AL.

By their Representatives,  
SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
P.O. Box 2938  
Minneapolis, MN 55402  
(612) 371-2106

Date 6 January 2005

By Katharine A. Jackson Huebsch


Katharine A. Jackson Huebsch

Reg. No. 47,670

**CERTIFICATE UNDER 37 CFR 1.8:** The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 10th day of January, 2005.

Name

Signature



Substitute Form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/082,925
Filing Date	February 26, 2002
First Named Inventor	More, John
Group Art Unit	1653
Examiner Name	Mohamed, Abdel

Sheet 1 of 1

Attorney Docket No: 697.004US2

**US PATENT DOCUMENTS**

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
--------------------	---------------------	------------------	---	----------------------------

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T <sup>2</sup>
--------------------	---------------------	------------------	---	----------------

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		KEYLER, DANIEL E., "Effects of Alpha-1-Acid Glycoprotein Administration on Propranolol Binding and Beta Blockade in Rats", <u>Biochemical Pharmacology</u> , Vol. 38, No. 7, (1989),1163-1168	
		KREMER, JOSEPHINA M., "Drug Binding to Human Alpha-1-acid Glycoprotein in Health and Disease", <u>Pharmacological Reviews</u> , Vol. 40, No. 1, (1988),1-47	
		SEABERG, DAVID C., "Effects of Alpha-1-acid Glycoprotein on the Cardiovascular Toxicity of Nortriptyline in a Swine Model", <u>Vet Hum Toxicol</u> , Vol. 33, No. 3, (June 1991),226-231	

**EXAMINER**

**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional) <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached